Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 457,500 shares, a growth of 90.3% from the December 31st total of 240,400 shares. Based on an average daily trading volume, of 3,640,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.2% of the shares of the company are sold short.

Virpax Pharmaceuticals Stock Performance

NASDAQ:VRPX traded down $0.01 during midday trading on Thursday, reaching $0.31. The stock had a trading volume of 510,607 shares, compared to its average volume of 520,959. Virpax Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $5.48. The firm has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.68.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals at the end of the most recent quarter. 32.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Maxim Group restated a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.